Ilhan Yusuf, Balcik Onur Yazdan, Guzel Halil Goksel, Onder Arif Hakan, Demir Bilgin, Baser Mehmet Nuri, Karadag Ibrahim, Ozbay Mehmet Fatih, Genc Tugrul Burak, Uzuntas Sahnura, Poyrazoglu Oguz, Beypinar Ismail, Ergun Yakup, Ozturk Banu
Department of Medical Oncology, Antalya City Hospital, Antalya 07080, Türkiye.
Department of Medical Oncology, Alanya Alaaddin Keykubat University, Antalya 07400, Türkiye.
World J Gastrointest Oncol. 2025 May 15;17(5):104341. doi: 10.4251/wjgo.v17.i5.104341.
Metastatic colorectal cancer (mCRC) is a global health challenge with a poor prognosis. Prognostic markers are critical for survival prediction.
To evaluate a novel tumor marker index (TMI) combining carcinoembryonic antigen and carbohydrate antigen 19-9.
This multicenter, retrospective study measured baseline carcinoembryonic antigen and carbohydrate antigen 19-9 levels to calculate a TMI as the geometric mean of values normalized to their upper limits of normal. Receiver operating characteristic curve analysis assessed TMI's prognostic accuracy, and patients were stratified into high-TMI (≥ 1.39) and low-TMI (< 1.39) groups. The primary endpoint was overall survival (OS), with progression-free survival and treatment response as secondary endpoints.
The study included 305 mCRC patients with a median follow-up of 22.9 months. The median OS for high-TMI patients was 29.5 months, significantly lower than the 45.6 months observed in the low-TMI group ( = 0.02). The 2-year OS rates for the high- and low-TMI groups were 59.4% and 72.9%, respectively. Median progression-free survival was also shorter for the high-TMI group (14.0 16.0 months, = 0.84). High TMI is an independent prognostic factor for worse OS.
TMI is a simple, cost-effective prognostic tool for mCRC, with high TMI associated with poorer survival outcomes.
转移性结直肠癌（mCRC）是一项全球性的健康挑战，预后较差。预后标志物对于生存预测至关重要。
评估一种结合癌胚抗原和糖类抗原19-9的新型肿瘤标志物指数（TMI）。
这项多中心回顾性研究测量了基线癌胚抗原和糖类抗原19-9水平，以计算TMI，即标准化至正常上限值的几何平均数。受试者工作特征曲线分析评估了TMI的预后准确性，并将患者分为高TMI（≥1.39）和低TMI（<1.39）组。主要终点为总生存期（OS），无进展生存期和治疗反应作为次要终点。
该研究纳入了305例mCRC患者，中位随访时间为22.9个月。高TMI患者的中位OS为29.5个月，显著低于低TMI组观察到的45.6个月（P = 0.02）。高TMI组和低TMI组的2年OS率分别为59.4%和72.9%。高TMI组的中位无进展生存期也较短（14.0对16.0个月，P = 0.84）。高TMI是OS较差的独立预后因素。
TMI是一种用于mCRC的简单、经济有效的预后工具，高TMI与较差的生存结果相关。
